Olfaction, BMI, and quality of life with cystic fibrosis combination therapy

This study performed a prospective cohort study analyzing 41 CF patient responses to the Cystic Fibrosis Questionnaire‐Revised (CFQ‐R) and the Sino‐Nasal Outcome Test 22 (SNOT‐22). It used Generalized estimating equations (GEE). Patients reported significant improvement in their sense of smell at follow‐up. The study results support the impression that ETI therapy improves CF‐associated rhinologic symptoms and reverses OI while improving rhinologic QoL. Sense of smell is not an independent mediator of improved QoL and BMI in this population, suggesting that other factors may have a stronger role. However, given the subjective improvement in the sense of smell, additional evaluation of OI using psychophysical chemosensory assessment will clarify the connection between olfaction, BMI, and QoL in PwCF.